Humanized monoclonal antibody armanezumab specific to N-terminus of pathological tau: characterization and therapeutic potency

BACKGROUND: The experience from clinical trials indicates that anti-Aβ immunotherapy could be effective in early/pre-clinical stages of AD, whereas at the late stages promoting the clearing of Aβ alone may be insufficient to halt the disease progression. At the same time, pathological tau correlates...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Mol Neurodegener
Autors principals: Agadjanyan, Michael G., Zagorski, Karen, Petrushina, Irina, Davtyan, Hayk, Kazarian, Konstantin, Antonenko, Maxim, Davis, Joy, Bon, Charles, Blurton-Jones, Mathew, Cribbs, David H., Ghochikyan, Anahit
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2017
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5418694/
https://ncbi.nlm.nih.gov/pubmed/28472993
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13024-017-0172-1
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars